Roche Holding AG has been keeping investors on edge with its fluctuating performance. The global pharmaceutical company recently made big moves by acquiring U.S. biopharma company
Poseida Therapeutics and launching Accu-Chek Smartguide in Europe. However, the excitement was brought down due to concerns about adverse side effects from its newly developed
obesity drug. These concerns have seen
Roche stocks taking a hit. Still, despite restraining factors, internal enthusiasm persists as Roche managed to retain outlook after two out of its three big hitters top sales expectations. It is also believed that
Morgan Stanley is bullish on this stock, positioning it as a 'good investment', and even amidst the concerns, obesity drug trial results had Roche shares jumping a bit. However, it is observed that the three-year returns and company earnings persist lower as Roche's stock has been underperforming recently. Interestingly, the recent developments have shaken up the competition in the pharma industry, particularly in the
obesity drug market, causing shares of competitors like Eli Lilly and Novo to slide. In direct response to this, Roche’s stock price saw a jump.
Roche Stocks News Analytics from Thu, 01 Feb 2024 08:00:00 GMT to Thu, 16 Jan 2025 01:04:00 GMT -
Rating 0
- Innovation 2
- Information 8
- Rumor -7
